Joseph L. Bundy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph L. Bundy has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Logan J. Everett
Office of Research and Development, Center for Computational Toxicology and Exposure, U.S. Environmental Protection Agency , Research Triangle Park , Durham, NC 27709
5 shared publications - Clinton M. Willis
U.S. Environmental Protection Agency
4 shared publications - Derik E. Haggard
Office of Research and Development, Center for Computational Toxicology and Exposure, U.S. Environmental Protection Agency , Research Triangle Park , Durham, NC 27709
4 shared publications - Imran Shah
Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA
4 shared publications - Joshua A. Harrill
Corteva Agriscience, Indianapolis, USA
4 shared publications - Richard S. Judson
U.S. Environmental Protection Agency
3 shared publications
Latest Publications
- 1 July 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (13) , 6671-6684
A Machine Learning Approach to Molecular Initiating Event Prediction Using High-Throughput Transcriptomic Chemical Screening Data
Improved scalability of high-throughput RNA-sequencing technologies has contributed to their proposed use in regulatory contexts for chemical hazard identification. However, the high dimensionality and size of these transcriptomic data sets present a formidable obstacle for utilizing these data to address gaps in chemical safety information. New bioinformatic approaches for extracting mechanistic insight from transcriptomic data sets are a critical need. Here, we present a framework for predicting molecular initiating events (MIE) from transcriptomic chemical bioactivity screens. This framework trains models to predict MIE activation using Machine Learning (MIEML). Classifiers were trained by integrating gene expression profiles, derived from chemical exposures in MCF-7 cells, with chemical-MIE annotations from RefChemDB, a database that identifies reference chemicals for molecular targets by aggregating data across multiple sources. Classifiers were trained to predict the activation of nine distinct MIEs using profiles derived from reference chemical exposures. Of the nine MIEs modeled, three yielded classifiers that performed significantly better than classifiers trained on randomly selected profiles (p value ≤ 0.1) and correctly predicted MIEs of training-excluded reference chemicals. These classifiers were then used to generate MIE predictions for 1750 test chemicals. These predictions showed significant overlap with those derived from targeted molecular bioassay data for estrogen receptor agonism, aryl hydrocarbon receptor agonism, and glucocorticoid receptor agonism. These results demonstrate the utility of this framework in predicting the MIE activation from large transcriptomic chemical screens.
- 1 July 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (13) , 6671-6684
A Machine Learning Approach to Molecular Initiating Event Prediction Using High-Throughput Transcriptomic Chemical Screening Data
Improved scalability of high-throughput RNA-sequencing technologies has contributed to their proposed use in regulatory contexts for chemical hazard identification. However, the high dimensionality and size of these transcriptomic data sets present a formidable obstacle for utilizing these data to address gaps in chemical safety information. New bioinformatic approaches for extracting mechanistic insight from transcriptomic data sets are a critical need. Here, we present a framework for predicting molecular initiating events (MIE) from transcriptomic chemical bioactivity screens. This framework trains models to predict MIE activation using Machine Learning (MIEML). Classifiers were trained by integrating gene expression profiles, derived from chemical exposures in MCF-7 cells, with chemical-MIE annotations from RefChemDB, a database that identifies reference chemicals for molecular targets by aggregating data across multiple sources. Classifiers were trained to predict the activation of nine distinct MIEs using profiles derived from reference chemical exposures. Of the nine MIEs modeled, three yielded classifiers that performed significantly better than classifiers trained on randomly selected profiles (p value ≤ 0.1) and correctly predicted MIEs of training-excluded reference chemicals. These classifiers were then used to generate MIE predictions for 1750 test chemicals. These predictions showed significant overlap with those derived from targeted molecular bioassay data for estrogen receptor agonism, aryl hydrocarbon receptor agonism, and glucocorticoid receptor agonism. These results demonstrate the utility of this framework in predicting the MIE activation from large transcriptomic chemical screens.
- 2 May 2025
- Published by Oxford University Press (OUP) in Toxicological Sciences
Incorporating Metabolic Competence into High-Throughput Profiling Assays
High-throughput profiling assays such as high-throughput phenotypic profiling (HTPP) with Cell Painting and high-throughput transcriptomics (HTTr) with TempO-Seq have been used to characterize the bioactivity and potential hazards associated with large inventories of chemicals. Although both methods offer broad coverage of molecular targets, a limitation is that the cell types used in these in vitro assays typically lack the xenobiotic metabolism capabilities of humans or laboratory animals used for in vivo testing. To address this limitation, this proof-of-concept study coupled the Alginate Immobilization of Metabolic Enzymes (AIME) platform to both assays and evaluated the impact of metabolism on chemical bioactivity in a breast cancer cell line, VM7Luc4E2. HTPP detected concentration-dependent increases in chemical bioactivity corresponding to increased estrogen receptor (ER) activation measured using an ER transactivation assay (ERTA) that had been previously coupled to the AIME platform in VM7Luc4E2 cells. Additionally, HTTr detected a greater number of active genes in the metabolic condition associated with increased ER activation. This corresponded to a greater number of active ER high-confidence (ERHC) gene signatures and/or metabolism-induced shifts in ERHC signature enrichment as a transcriptomic readout of ER activity. This study demonstrates that the high-throughput profiling assays can detect changes in chemical bioactivity between parent compounds and metabolites generated using the AIME platform in a reproducible way. Incorporating metabolic competence into high-throughput profiling assays will better inform next-generation risk assessment by capturing potential metabolite-based changes in bioactivity of test chemicals that may be missed by current screening approaches.
- 2 May 2025
- Published by Oxford University Press (OUP) in Toxicological Sciences
Incorporating Metabolic Competence into High-Throughput Profiling Assays
High-throughput profiling assays such as high-throughput phenotypic profiling (HTPP) with Cell Painting and high-throughput transcriptomics (HTTr) with TempO-Seq have been used to characterize the bioactivity and potential hazards associated with large inventories of chemicals. Although both methods offer broad coverage of molecular targets, a limitation is that the cell types used in these in vitro assays typically lack the xenobiotic metabolism capabilities of humans or laboratory animals used for in vivo testing. To address this limitation, this proof-of-concept study coupled the Alginate Immobilization of Metabolic Enzymes (AIME) platform to both assays and evaluated the impact of metabolism on chemical bioactivity in a breast cancer cell line, VM7Luc4E2. HTPP detected concentration-dependent increases in chemical bioactivity corresponding to increased estrogen receptor (ER) activation measured using an ER transactivation assay (ERTA) that had been previously coupled to the AIME platform in VM7Luc4E2 cells. Additionally, HTTr detected a greater number of active genes in the metabolic condition associated with increased ER activation. This corresponded to a greater number of active ER high-confidence (ERHC) gene signatures and/or metabolism-induced shifts in ERHC signature enrichment as a transcriptomic readout of ER activity. This study demonstrates that the high-throughput profiling assays can detect changes in chemical bioactivity between parent compounds and metabolites generated using the AIME platform in a reproducible way. Incorporating metabolic competence into high-throughput profiling assays will better inform next-generation risk assessment by capturing potential metabolite-based changes in bioactivity of test chemicals that may be missed by current screening approaches.
- 23 August 2024
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 202 (1) , 103-122
Signature analysis of high-throughput transcriptomics screening data for mechanistic inference and chemical grouping
High-throughput transcriptomics (HTTr) uses gene expression profiling to characterize the biological activity of chemicals in in vitro cell-based test systems. As an extension of a previous study testing 44 chemicals, HTTr was used to screen an additional 1751 unique chemicals from the EPA’s ToxCast collection in MCF7 cells using eight concentrations and an exposure duration of 6 hours. We hypothesized that concentration-response modeling of signature scores could be used to identify putative molecular targets and cluster chemicals with similar bioactivity. Clustering and enrichment analyses were conducted based on signature catalog annotations and ToxPrint chemotypes to facilitate molecular target prediction and grouping of chemicals with similar bioactivity profiles. Enrichment analysis based on signature catalog annotation identified known mechanisms-of-action (MeOAs) associated with well-studied chemicals and generated putative MeOAs for other active chemicals. Chemicals with predicted MeOAs included those targeting estrogen receptor (ER), glucocorticoid receptor (GR), retinoic acid receptor (RAR), the NRF2/KEAP/ARE pathway, AP-1 activation and others. Using reference chemicals for ER modulation, the study demonstrated that HTTr in MCF7 cells was able to stratify chemicals in terms of agonist potency, distinguish ER agonists from antagonists, and cluster chemicals with similar activities as predicted by the ToxCast ER Pathway model. Uniform manifold approximation and projection (UMAP) embedding of signature-level results identified novel ER modulators with no ToxCast ER Pathway model predictions. Finally, UMAP combined with ToxPrint chemotype enrichment was used to explore the biological activity of structurally-related chemicals. The study demonstrates that HTTr can be used to inform chemical risk assessment by determining in vitro points-of-departure, predicting chemicals’ molecular mechanism(s)-of-action (MeOA) and grouping chemicals with similar bioactivity profiles.
- 23 August 2024
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 202 (1) , 103-122
Signature analysis of high-throughput transcriptomics screening data for mechanistic inference and chemical grouping
High-throughput transcriptomics (HTTr) uses gene expression profiling to characterize the biological activity of chemicals in in vitro cell-based test systems. As an extension of a previous study testing 44 chemicals, HTTr was used to screen an additional 1751 unique chemicals from the EPA’s ToxCast collection in MCF7 cells using eight concentrations and an exposure duration of 6 hours. We hypothesized that concentration-response modeling of signature scores could be used to identify putative molecular targets and cluster chemicals with similar bioactivity. Clustering and enrichment analyses were conducted based on signature catalog annotations and ToxPrint chemotypes to facilitate molecular target prediction and grouping of chemicals with similar bioactivity profiles. Enrichment analysis based on signature catalog annotation identified known mechanisms-of-action (MeOAs) associated with well-studied chemicals and generated putative MeOAs for other active chemicals. Chemicals with predicted MeOAs included those targeting estrogen receptor (ER), glucocorticoid receptor (GR), retinoic acid receptor (RAR), the NRF2/KEAP/ARE pathway, AP-1 activation and others. Using reference chemicals for ER modulation, the study demonstrated that HTTr in MCF7 cells was able to stratify chemicals in terms of agonist potency, distinguish ER agonists from antagonists, and cluster chemicals with similar activities as predicted by the ToxCast ER Pathway model. Uniform manifold approximation and projection (UMAP) embedding of signature-level results identified novel ER modulators with no ToxCast ER Pathway model predictions. Finally, UMAP combined with ToxPrint chemotype enrichment was used to explore the biological activity of structurally-related chemicals. The study demonstrates that HTTr can be used to inform chemical risk assessment by determining in vitro points-of-departure, predicting chemicals’ molecular mechanism(s)-of-action (MeOA) and grouping chemicals with similar bioactivity profiles.
- 2 December 2023
- Published by Elsevier in Toxicology
- Vol. 501, 153694
Exploring the effects of experimental parameters and data modeling approaches on in vitro transcriptomic point-of-departure estimates
- 2 December 2023
- Published by Elsevier in Toxicology
- Vol. 501, 153694
Exploring the effects of experimental parameters and data modeling approaches on in vitro transcriptomic point-of-departure estimates
- Top Cited PapersOpen Access
- 4 February 2021
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 181 (1) , 68-89
High-Throughput Transcriptomics Platform for Screening Environmental Chemicals
New approach methodologies (NAMs) that efficiently provide information about chemical hazard without using whole animals are needed to accelerate the pace of chemical risk assessments. Technological advancements in gene expression assays have made in vitro high-throughput transcriptomics (HTTr) a feasible option for NAMs-based hazard characterization of environmental chemicals. In this study, we evaluated the Templated Oligo with Sequencing Readout (TempO-Seq) assay for HTTr concentration-response screening of a small set of chemicals in the human-derived MCF7 cell model. Our experimental design included a variety of reference samples and reference chemical treatments in order to objectively evaluate TempO-Seq assay performance. To facilitate analysis of these data, we developed a robust and scalable bioinformatics pipeline using open-source tools. We also developed a novel gene expression signature-based concentration-response modeling approach and compared the results to a previously implemented workflow for concentration-response analysis of transcriptomics data using BMDExpress. Analysis of reference samples and reference chemical treatments demonstrated highly reproducible differential gene expression signatures. In addition, we found that aggregating signals from individual genes into gene signatures prior to concentration-response modeling yielded in vitro transcriptional biological pathway altering concentrations (BPACs) that were closely aligned with previous ToxCast high-throughput screening assays. Often these identified signatures were associated with the known molecular target of the chemicals in our test set as the most sensitive components of the overall transcriptional response. This work has resulted in a novel and scalable in vitro HTTr workflow that is suitable for high-throughput hazard evaluation of environmental chemicals.
- 4 February 2021
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 181 (1) , 68-89
Top Cited PapersOpen AccessHigh-Throughput Transcriptomics Platform for Screening Environmental Chemicals
New approach methodologies (NAMs) that efficiently provide information about chemical hazard without using whole animals are needed to accelerate the pace of chemical risk assessments. Technological advancements in gene expression assays have made in vitro high-throughput transcriptomics (HTTr) a feasible option for NAMs-based hazard characterization of environmental chemicals. In this study, we evaluated the Templated Oligo with Sequencing Readout (TempO-Seq) assay for HTTr concentration-response screening of a small set of chemicals in the human-derived MCF7 cell model. Our experimental design included a variety of reference samples and reference chemical treatments in order to objectively evaluate TempO-Seq assay performance. To facilitate analysis of these data, we developed a robust and scalable bioinformatics pipeline using open-source tools. We also developed a novel gene expression signature-based concentration-response modeling approach and compared the results to a previously implemented workflow for concentration-response analysis of transcriptomics data using BMDExpress. Analysis of reference samples and reference chemical treatments demonstrated highly reproducible differential gene expression signatures. In addition, we found that aggregating signals from individual genes into gene signatures prior to concentration-response modeling yielded in vitro transcriptional biological pathway altering concentrations (BPACs) that were closely aligned with previous ToxCast high-throughput screening assays. Often these identified signatures were associated with the known molecular target of the chemicals in our test set as the most sensitive components of the overall transcriptional response. This work has resulted in a novel and scalable in vitro HTTr workflow that is suitable for high-throughput hazard evaluation of environmental chemicals.
- Open Access
- 3 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0217042
RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes
Kidney failure occurs in 5–13% of individuals with sickle cell disease and is associated with early mortality. Two APOL1 alleles (G1 and G2) have been identified as risk factors for sickle cell disease nephropathy. Both risk alleles are prevalent in individuals with recent African ancestry and have been associated with nephropathic complications in other diseases. Despite the association of G1 and G2 with kidney dysfunction, the mechanisms by which these variants contribute to increased risk remain poorly understood. Previous work in zebrafish models suggest that the G2 risk allele functions as a dominant negative, whereas the G1 allele is a functional null. To understand better the cellular pathology attributed to APOL1 G2, we investigated the in vivo effects of the G2 risk variant on distinct cell types using RNA sequencing. We surveyed APOL1 G2 associated transcriptomic alterations in podocytes and vascular endothelial cells isolated from zebrafish larvae expressing cell-type specific reporters. Our analysis identified many transcripts (n = 7,523) showing differential expression between APOL1 G0 (human wild-type) and APOL1 G2 exposed podocytes. Conversely, relatively few transcripts (n = 107) were differentially expressed when comparing APOL1 G0 and APOL1 G2 exposed endothelial cells. Pathway analysis of differentially expressed transcripts in podocytes showed enrichment for autophagy associated terms such as “Lysosome” and “Phagosome”, implicating these pathways in APOL1 G2 associated kidney dysfunction. This work provides insight into the molecular pathology of APOL1 G2 nephropathy which may offer new therapeutic strategies for multiple disease contexts such as sickle cell nephropathy.
- 3 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0217042
Open AccessRNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes
Kidney failure occurs in 5–13% of individuals with sickle cell disease and is associated with early mortality. Two APOL1 alleles (G1 and G2) have been identified as risk factors for sickle cell disease nephropathy. Both risk alleles are prevalent in individuals with recent African ancestry and have been associated with nephropathic complications in other diseases. Despite the association of G1 and G2 with kidney dysfunction, the mechanisms by which these variants contribute to increased risk remain poorly understood. Previous work in zebrafish models suggest that the G2 risk allele functions as a dominant negative, whereas the G1 allele is a functional null. To understand better the cellular pathology attributed to APOL1 G2, we investigated the in vivo effects of the G2 risk variant on distinct cell types using RNA sequencing. We surveyed APOL1 G2 associated transcriptomic alterations in podocytes and vascular endothelial cells isolated from zebrafish larvae expressing cell-type specific reporters. Our analysis identified many transcripts (n = 7,523) showing differential expression between APOL1 G0 (human wild-type) and APOL1 G2 exposed podocytes. Conversely, relatively few transcripts (n = 107) were differentially expressed when comparing APOL1 G0 and APOL1 G2 exposed endothelial cells. Pathway analysis of differentially expressed transcripts in podocytes showed enrichment for autophagy associated terms such as “Lysosome” and “Phagosome”, implicating these pathways in APOL1 G2 associated kidney dysfunction. This work provides insight into the molecular pathology of APOL1 G2 nephropathy which may offer new therapeutic strategies for multiple disease contexts such as sickle cell nephropathy.
- 8 November 2018
- Published by Wiley in Journal of Comparative Neurology
- Vol. 527 (2) , 462-475
Sex‐biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: A multi‐omic analysis
Alzheimer's disease is a progressive neurodegenerative disorder and the most common form of dementia. Like many neurological disorders, Alzheimer's disease has a sex‐biased epidemiological profile, affecting approximately twice as many women as men. The cause of this sex difference has yet to be elucidated. To identify molecular correlates of this sex bias, we investigated molecular pathology in females and males using the 5XFamilial Alzheimer's disease mutations (5XFAD) genetic mouse model of Alzheimer's disease. We profiled the transcriptome and proteome of the mouse hippocampus during early stages of disease development (1, 2, and 4 months of age). Our analysis reveals 42 genes that are differentially expressed between disease and wild‐type animals at 2 months of age, prior to observable plaque deposition. In 4‐month‐old animals, we detect 1,316 differentially expressed transcripts between transgenic and control 5XFAD mice, many of which are associated with immune function. Additionally, we find that some of these transcriptional perturbations are correlated with altered protein levels in 4‐month‐old transgenic animals. Importantly, our data indicate that female 5XFAD mouse exhibit more profound pathology than their male counterparts as measured by differences in gene expression. We also find that the 5XFAD transgenes are more highly expressed in female 5XFAD mice than their male counterparts, which could partially account for the sex‐biased molecular pathology observed in this dataset.
- 8 November 2018
- Published by Wiley in Journal of Comparative Neurology
- Vol. 527 (2) , 462-475
Sex‐biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: A multi‐omic analysis
Alzheimer's disease is a progressive neurodegenerative disorder and the most common form of dementia. Like many neurological disorders, Alzheimer's disease has a sex‐biased epidemiological profile, affecting approximately twice as many women as men. The cause of this sex difference has yet to be elucidated. To identify molecular correlates of this sex bias, we investigated molecular pathology in females and males using the 5XFamilial Alzheimer's disease mutations (5XFAD) genetic mouse model of Alzheimer's disease. We profiled the transcriptome and proteome of the mouse hippocampus during early stages of disease development (1, 2, and 4 months of age). Our analysis reveals 42 genes that are differentially expressed between disease and wild‐type animals at 2 months of age, prior to observable plaque deposition. In 4‐month‐old animals, we detect 1,316 differentially expressed transcripts between transgenic and control 5XFAD mice, many of which are associated with immune function. Additionally, we find that some of these transcriptional perturbations are correlated with altered protein levels in 4‐month‐old transgenic animals. Importantly, our data indicate that female 5XFAD mouse exhibit more profound pathology than their male counterparts as measured by differences in gene expression. We also find that the 5XFAD transgenes are more highly expressed in female 5XFAD mice than their male counterparts, which could partially account for the sex‐biased molecular pathology observed in this dataset.